Condition 1: breast cancer. Condition 2: colon cancer. Malignant neoplasm of breast Malignant neoplasm of colon
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: In the intervention group, piroxicam gel (0.5%, Sobhan Pharmaceuticals, Iran) will be used twice daily, 1 gram = two fingertip units (FTU) each
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Stage 2 and 3 colon cancer patients Triple-negative breast cancer patients with residual disease after surgery
Exclusion criteria
Exclusion criteria: Presence of grade 2 or higher neuropathy skin conditions that, in the opinion of the physician, may affect the hands or feet or complicate assessment during the study period Use of pyridoxine or renin-angiotensin system inhibitors History of hypersensitivity or anaphylactic reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) History of asthma or other allergic-type reactions after taking aspirin or other NSAIDs Patients taking oral or topical NSAIDs or aspirin for other conditions Concomitant illnesses, including severe infections, that may compromise the patient's ability to safely perform the procedures specified in this protocol Serious medical or psychiatric conditions that may limit the patient's ability to adhere to the protocolDiscontinuation of medication or placebo during the treatment period Unwillingness to continue in the study at any stage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grade 2 and above hand-foot syndrome. Timepoint: Patients will be assessed by a cancer specialist for the occurrence of HFS at the beginning of chemotherapy and at the end of each chemotherapy cycle based on the World Health Organization HFS assessment scale (WHO score) for 4 cycles. Method of measurement: World Health Organization HFS Assessment Scale (WHO Scoring). | — |
Secondary
| Measure | Time frame |
|---|---|
| When does hand-foot syndrome occur?. Timepoint: After 4 cycles of capecitabine treatment. Method of measurement: Hand-foot syndrome related quality of life questionnaire number 14(HFS-14). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirhossein Darvishi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed